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A B S T R A C T
Objective: We assessed the curative effect of a second curettage in patients with persistent hCG serum
levels after first curettage for a gestational trophoblastic disease (GTD).
Study Design: This prospective observational study used the data of the Belgian register for GTD between
July 2012 and January 2017. We analysed the data of patients who underwent a second curettage. We
included 313 patients in the database. Primary endpoints were need for second curettage and
chemotherapy.
Results: Thirty-seven patients of the study population (12 %) underwent a second curettage. 20 had
persistent human chorionic gonadotropin hormone (hCG) elevation before second curettage. Of them, 9
patients (45 %) needed no further treatment afterwards. Eleven patients (55 %) needed further
chemotherapy. Nine (82 %) were cured with single-agent chemotherapy and 2 patients (18 %) needed
multi-agent chemotherapy.
Of the 37 patients, patients with hCG levels below 5000 IU/L undergoing a second curettage were cured
without chemotherapy in 65 % versus 45 % of patients with hCG level more than 5000 IU/L. Of the ten
patients with a hCG level below 1000 IU/L, eight were cured without chemotherapy.
Conclusions: Patients with post-mole gestational trophoblastic neoplasia can benefit from a second
curettage to avoid chemotherapy, especially when the hCG level is lower than 5000 IU/L.
© 2020 Elsevier B.V. All rights reserved.
Introduction
Gestational trophoblastic disease (GTD) represents a spectrum
of different premalignant and malignant diseases. The premalig-
nant diseases are subdivided in complete (CM) and partial
hydatidiform mole (PM). Invasive mole, choriocarcinoma, placen-
tal site trophoblastic tumour (PSTT) and epithelioid trophoblastic
tumour (ETT) represent the malignant part [1–3]. The malignant
diseases, also known as’ gestational trophoblastic neoplasia (GTN)’,
can arise after any type of pregnancy [4].
The prevalence of gestational trophoblastic disease is about 1 in
1 000 pregnancies for CM and 3 in 1 000 pregnancies for PM [2]. CM
has a 15–20 % risk of becoming malignant [2,3,5]. Less than 1 % of
the PM become malignant [2,6–9]. With a cure rate of almost 100 %,
low risk GTN are among the best prognostic solid cancers [2]. Fatal
cases due to severe bleeding at the onset of the disease, late
presentation, incorrect risk classification, drug resistance or drug
complications are becoming very rare [2,4].
The diagnosis of molar pregnancy is made after careful pathologic
examination of curettage material [2,3]. Afterwards, human chori-
onic gonadotropin hormone (hCG) monitoring is essential for early
detection of malignant transformation [3,10]. In case of post-mole
neoplasia, the main treatment options are chemotherapy or surgery.
Indications for treatment with chemotherapy are: a plateaued or
rising hCG, histological diagnosis of choriocarcinoma, [2,3].
Contents lists available at ScienceDirect
European Journal of Obstetrics & Gynecology and
Reproductive Biology
journal homepage: www.else vie r .com/ locate /e jogrb* Corresponding author at: Herestraat 49, B-3000, UZ Leuven, Belgium.
E-mail address: Sileny.han@uzleuven.be (S.N. Han).
https://doi.org/10.1016/j.ejogrb.2020.12.001
0301-2115/© 2020 Elsevier B.V. All rights reserved.Currently, the benefit of a second curettage in patients with
post-mole gestational trophoblastic neoplasia remains controver-






















































A. Vandewal, K. Delbecque, A.S. Van Rompuy et al. European Journal of Obstetrics & Gynecology and Reproductive Biology 257 (2021) 95–99herapeutic effect and allowed to omit the need for chemotherapy
n about 40 % of the patients with low-risk, non-metastatic post
ole GTN [11].
The aim of this study is to investigate the curative effect of a
econd curettage after molar pregnancy (with and without
rogression to GTN and their need for chemotherapy).
aterials and methods
elgian register for trophoblastic diseases
A Belgian National register for gestational trophoblastic
iseases [12] was initiated in July 2012 (Belgian Register for
rophoblastic Diseases (www.mole-chorio-bgog.eu)), and hosted
y the Belgian Gynaecological Oncology Group (BGOG).
The aim of this prospective registration study is twofold. First to
egister patients diagnosed with gestational trophoblastic disease;
nd second to offer central pathology review and advise about
he treatment and follow-up of these patients. Improving the
iagnosis, treatment and outcome of patients with GTN is the
ltimate goal and has proven useful in other countries [2,5].
Two reference centres were initiated: one for the French-
peaking part of Belgium (Centre Hospitalier Universitaire de
iège) and one for the Flemish-speaking part (University Hospitals
euven). All patients with a diagnosis of gestational trophoblastic
isease (after pathology confirmation) are eligible. The local
ractitioner contacts a reference centre when a molar pregnancy is
iagnosed and remains treating physician. Patient referral to the
eference centre is not mandatory. The patient is asked to sign an
nformed consent and to complete a questionnaire on medical
istory and demographic data. The tumour sample, mostly
btained by curettage, is revised by one of the central pathologists:
r. Delbecque and Pr. Delvenne (University Hospital of Liège,
iège), Pr. Marbaix (University Hospital Saint-Luc, Brussels),
r. Noel (Erasmus Hospital, Brussels); Pr. Moerman and Pr Van
ompuy (University Hospitals Leuven, KU Leuven, Leuven). After
entral confirmation of molar pregnancy, weekly serum hCG (IU/L)
s monitored with supervision by the reference centre for early
etection of abnormal evolution. The reference centre advises on
reatment or follow-up. hCG normalisation curves of this dataset
ere published previously [13].
When abnormal evolution is observed, the local practitioner is
ontacted. The hCG level needs to be analysed weekly till the level
s normalised ( 2.0 IU/L) for 2 consecutive weeks for patients
ith partial and complete mole. The follow-up for patients with
omplete mole is extended for a period of 6 months (monthly hCG).
ollow-up is shorter for patients with partial mole because the risk
or subsequent GTN is less than 1:3000 [14]. Serum hCG levels
ere determined by the β subunit radioimmunoassay method. The
ssay used is made according to local laboratory preferences.
ersistent hCG elevation was defined as plateauing hCG levels (four
alues, three weeks of interval) or rising hCG levels (three values,
wo weeks of interval) according to the FIGO criteria [2].
For the current analysis, we included all women who underwent
econd curettage. The treating physician decided whether or not a
econd curettage was performed. For this study we assessed: in-
icationsofsecondcurettage,hCGlevels atthemomentof thesecond
urettage, complications and subsequent treatment. The pathology
eports of the first and second curettage were also compared.
Summary statistics of these patients are expressed descriptive-
reasons (no pathology report, no information about treatment or
lost to follow-up). Table 1 shows our results after review of
pathology. There were 24 pathology slides without review, 5
inconclusive results and 27 missing data. Fig. 1 shows overall need
for second curettage and chemotherapy. The overall need for
chemotherapy was 22 % (69 patients) in our population.
A total of 37 women underwent second curettage. Mean time
between the first and second curettage was 49 days (range: 1–
217 days). In Fig. 2 outcome of second curettage was shown.
20 patients had persistent hCG elevation, of them 55 % needed
chemotherapy after the second curettage. 45 % was cured without
chemotherapy. Eight patients received their chemotherapy after
the second curettage, three before. There was no reason mentioned
for giving the chemotherapy before the second curettage. There
were also five patients who received chemotherapy without notion
of persistent hCG elevation. Three patients had a complete or
Table 1
Pathology results after review.












Fig. 1. Outcome of patients registered with gestational trophoblastic disease.Fig. 2. Outcome of patients with second curettage.y or as a percentage.
esults
Between July 2012 and January 2017, 330 patients were
egistered. After review, 17 patients were excluded for various96
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Three were treated with methotrexate, the other two received
multi-agent chemotherapy.
Eleven patients (55 %) needed further chemotherapy after their
second curettage.
Of them, 9 (82 %) were cured with single-agent chemotherapy
(low dose methotrexate or dactinomycin) and 2 patients (18 %)
needed multi-agent chemotherapy. The pathology report of the
patients who needed multi-agent chemotherapys showed one
invasive mole and one PSTT.
Fifteen women underwent a second curettage for residual
molar tissue in the uterus (40 %). Other reasons for second
curettage were: persistent high hCG whether or not with residual
molar tissue (n = 12; 32 %); persistent vaginal bleeding (n = 4; 11 %),
other (n = 3; 8%) and missing data (n = 3; 8%).
Complications were reported for 2 patients. One patient
suffered from a uterine infection with ARDS (acute respiratory
distress syndrome), another patient had a haemorrhage (grade of
seriousness not mentioned). No uterine perforation was men-
tioned.
Fig. 3 shows the comparison of the pathology reports after first
and second curettage. Twenty-two patients (59 %) had same results
in both curettages. For three patients (8 %), there was an upgrading
(e.g. CM to choriocarcinoma), in four patients (11 %) we found a
downgrading (e.g. PM to benign pathology). In 16 % there were
missing data or unknown pathology report of the first curettage.
The mean hCG normalisation time of our overall study
population was 12.6 weeks (range: 3–66 weeks). We found a
serum hCG normalisation of 17 % within 6 weeks, 60 % within 11
weeks and 93 % within 25 weeks after the first evacuation. When
we investigated our population without chemotherapy or second
curettage (low-risk), mean hCG normalisation time was 10 weeks.
Women who underwent a second curettage and did not need
chemotherapy thereafter had a mean hCG normalisation time of
14.5 weeks. With chemotherapy, this mean normalisation time
increased to an average of 19 weeks.
Median hCG level at the moment of the second curettage was 3
432 IU/L (range 37–86 062 IU/L; missing data n = 9). Women who
needed chemotherapy after their second curettage had a median
hCG of 3 400 IU/L (range 37–80 192 IU/L). Eleven patients had a hCG
level >5 000 IU/L, 17 patients had a hCG level <5 000 IU/L. In the
first group, 5 patients were cured without chemotherapy (45 %)
whereas patients with hCG levels <5 000 IU/L undergoing a second
curettage were cured without chemotherapy in 65 % (11 patients).
Of the ten patients with a hCG level below 1 000 IU/L, eight patients
were cured without chemotherapy.
Centralisation
Based on birth rates in Belgium and based on epidemiological
date forEuropeancountries, there is an estimated prevalence of 100–
150 molar pregnancies a year [15]. A retrospective study of theFig. 3. Inner circle: first curettage pathology report, outer circle: second curettage pathology report. Legend: PM (partial mole), CM (complete mole), Chorioca
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egistered between 2005 and 2007 [15]. Since epidemiologically
he incidence of PM is three times the incidence of the CM, it is
oteworthy that in our database, we found more CM (147) than PM
85). This could be due to a referral bias linked to the fact that PM are
onsidered as more’ benign’ and less harmful than CM and hence are
ess signed up to the Belgian Registry. Besides, the histopathological
iagnosis of partial mole is difficult, often confused with hydropic
bortion and other chromosomic abnormalities.
An objective of this registry was to investigate the beneficial
ffect of centralisation of this rare and specific disease in Belgium,
hich has never been done before. Nevertheless, centralisation has
roven its significance in other countries. The Department of
ealth and the Royal College of Obstetrics and Gynaecology
stablished a registration and follow-up system in the UK in 1972.
ince then patients with GTD are nationally registered and
creened within the following three centres (Charing Cross
ospital in London, Weston Park Hospital in Sheffield and
inewells Hospital in Dundee) [16–20]. In the Netherlands, there
ere 2 122 patients registered in the Dutch Central Registry for
ydatidiform Moles Radboud University Nijmegen Medical
entre) between 1987 and 2003 [5]. In France, Le Centre de
éférence des Maladies trophoblastiques was established in 1999
n Lyon [21].
econd curettage
In this study, we evaluated the effect of a second curettage. We
nvestigated the need for chemotherapy after a second evacuation
nd its eventual debulking effect.
In the literature, there is no consensus about a second curettage.
ure rate of a second curettage in the literature varies from 9.4%–
3% (Table 2) [5,11,18,22]. Van Trommel et al. performed a
etrospective cohort survey in a group of 294 patients with PTD
persistent trophoblastic disease). Eighty-five patients underwent
 second curettage, 209 patients were considered as control group.
hey found a significant difference between the two groups. 9.4 %
f patients with PTD needed no further chemotherapy after their
econd curettage, whereas 100 % of the control group needed
hemotherapy. They also found a debulking effect in patients who
equired further chemotherapy. These women needed less cycles
f chemotherapy. The indication for repeat curettage was vaginal
leeding only in 60 % of patients and abnormal hCG levels or
vidence of retained tissue in 37.6 % of patients [5]. In their study, a
econd curettage had a major complication rate (uterine perfora-
ion or bleeding) of 4.8 % [5]. In the study of Pezeshki et al., 4 075
atients were registered, and 544 patients had a second evacuation
erformed. 21 % required chemotherapy thereafter. The indication
or the second curettage varied, mainly for vaginal bleeding.
ezeshki et al. found in their prospective study that 68 % of the
atients with PTD based on elevated hCG levels only, were cured
ith a second curettage. Need for chemotherapy was more likely in
atients with hCG > 1 500 IU/L and histological evidence of PTD
18]. Osborne et al. as well performed a recent study about second
urettage in low-risk GTN patients. Of their study population of 60
omen, there was no need for additional chemotherapy in 40 %.
Nevertheless, a complication rate of 10 % was noted with one
uterine perforation and five uterine haemorrhages [11]. In the
small study by Yarandi et al., there was a cure rate of 83 % after
second curettage [22].
Our study population with persistent hCG elevation had a cure
rate of 45 % after second curettage, meaning that 9 patients
possibly evaded treatment with chemotherapy, associated side
effects and toxicity. Patients who needed chemotherapy, were
cured with single agent chemotherapy in 82 % of cases. Because of
this small number of patients and different treatment schemes,
this outcome cannot be easily assigned as a debulking effect. As
this was a descriptive study, we did not interfere with the
treatment and we could not measure the implications of doing a
second curettage in patients only with persistent high hCG
compared to a control group. We should consider the fact that a
second curettage could be done for a few’ wrong’ reasons. Some
patients received their second curettage before they were
registered and thus without advice of the referral centre. In our
study, the main indication for second curettage was residual molar
tissue and not persistent high hCG. Also, vaginal bleeding was a
main reason to do a second curettage. For twelve patients,
persistent high hCG was specifically mentioned as main reason for
second curettage. There is no mention of performed ultrasound
examination after the first curettage (completeness of evacuation).
Our range of hCG level was wide (37 IU/L to 86 062 IU/L) and often a
lot more than the proposed upper limit of 5 000 IU/L for a second
curettage [2].
As a recent study of Osborne et al. proved, surgical cure rate was
higher with lower hCG levels. They found a response rate of 53 % in
patients with hCG levels between 100 and 1 500 IU/L and 0 %
in patients with hCG levels above 100 000 IU/L [11]. Patients in our
study with a hCG level less than 5 000 IU/L had a cure rate of 65 %
without chemotherapy after their second curettage versus 45 %
when hCG was higher than 5 000 IU/L [2]. Of the ten patients with a
hCG level below 1 000 IU/L, eight were cured without chemother-
apy. A study at the Sheffield Gestational Trophoblastic Disease
Center between 1991 and 1993 set the cut-off of the hCG level at 5
000 IU/L, with more chance of surgical cure in patients with hCG
level of less than 5 000 IU/L [18].
More recent studies talk about cut-off rates of 1 500 IU/L
(urinary) [18]. Savage et al. recommend a second curettage only
when there is a proven residual mass in the uterus, hCG is less than
5 000 IU/L and patients are well informed about relative risks and
benefit of the procedure [23]. Chance of needing chemotherapy
after second curettage was more than 50 % [2,23] when the hCG
level exceeds 5 000 IU/L.
Taylor et al. found, in a small study (35 patients), a spontaneous
normalisation of hCG level in 86 % of patients with molar
pregnancy and raised but falling hCG level after six months
[24]. Can we just wait with our low risk patients? We also should
put the risks of a curettage (e.g. infection, haemorrhage, uterine
perforation) together with the high cure rate and safety of
chemotherapy [2]. Women with gestational trophoblastic disease
are generally young and have fertility wish. Is a second curettage
compromising their fertility and slowing down their child wish
because the delay of chemotherapy thereafter? We want to
able 2
ure rate of 2nd curettage as reported in the literature. Cure is defined as no additional chemotherapy needed.Study N second curettage Percentage of cured patients after second curettage
van Trommel et al. [5] 85 9.4 %
Pezeshki et al. [18] 544 67.6 %
Osborne et al. [11] 60 40 %
Yarandi et al. [22] 12 83 %
Current study 37 57 %
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treatment with a second curettage.
What is the ratio of patients with initial GTD (mole) that meets
the criteria of post-mole GTN that have been cured with a second
curettage instead of receiving chemotherapy?
Indeed, What is a persistent GTD?
- Is it a mole that has not been incompletely evacuated during the
first curettage?
- Is it a post mole GTN with rising HCG that occurs after a
complete evacuation (assessed by US after the first curettage).
- A mixed of both?
Patients with post-mole gestational trophoblastic neoplasia
with persistent hCG level can benefit from a second curettage to
avoid chemotherapy, especially when hCG level is lower than 5 000
IU/L and even more if hCG is below 1 000 IU/L. Randomised
controlled studies are needed to confirm this observation.
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